Current Report Filing (8-k)
October 06 2020 - 9:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
October
6, 2020
AIM
IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001
- 27072
|
|
52-0845822
|
(state
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
2117
SW Highway 484, Ocala FL
|
|
34473
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (352) 448-7797
AIM
ImmunoTech Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
AIM
|
|
NYSE
American
|
Item
8.01. Other Events.
AIM
ImmunoTech Inc. (“AIM” or the “Company”) received Institutional Review Board (“IRB”) approval
for the expansion of its AMP-511 Expanded Access Program (“EAP”) clinical trial for Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (“ME/CFS”) to include patients previously diagnosed with SARS-CoV-2, but who still demonstrate chronic
fatigue-like symptoms. These patients — commonly referred to as “Long Haulers” because of the persistence of
their symptoms — will be able to receive Ampligen treatments alongside the ME/CFS patients in the EAP. AIM is currently
preparing the IRB-approved protocol amendment for submission to the U.S. Food and Drug Administration (“FDA”). For
more information please see the October 6, 2020 press release, a copy of which is furnished herewith as Exhibit 99.1.
Cautionary
Statement
This
report on Form 8-K, including Exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act (PSLRA) of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate”
and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify
forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. For example,
the FDA could require changes to the protocol amendment and testing will be required to determine whether or not Ampligen will
assist in the treatment of COVID-19 induced CFS-like cases. Among other things, for those statements, we claim the protection
of safe harbor for forward-looking statements contained in the PSLRA. We do not undertake to update any of these forward-looking
statements to reflect events or circumstances that occur after the date hereof. Human clinical trials will be necessary to prove
whether or not Ampligen will be efficacious in humans. No assurance can be given as to whether current or planned immuno-oncology
clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory
approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation
of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug.
Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any
useful data or require additional funding. No assurance can be given that future studies will not result in findings that are
different from those reported in the studies referenced.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AIM IMMUNOTECH INC.
|
|
|
|
October
6, 2020
|
By:
|
/s/
Thomas K. Equels
|
|
|
Thomas
K. Equels, CEO
|
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Sep 2023 to Sep 2024